Immuneering Corp

IMRXSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1790340

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenues	—	—	$317.0K	$2.1M	$2.3M
Cost of Revenue	—	—	$158.1K	$1.2M	$1.3M
Gross Profit	—	—	$158.8K	$926.9K	$1.0M
Research and Development Expense	$48.0M	$41.6M	$36.3M	$26.5M	$15.0M
Operating Expenses	$64.1M	$58.4M	$51.9M	$34.8M	$18.1M
Operating Income (Loss)	-$64.1M	-$58.4M	-$51.7M	-$33.9M	-$17.1M
Other Nonoperating Income (Expense)	$441.5K	$1.3M	$216.8K	-$127.1K	-$127.1K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$52.7M	$102.6M	$122.4M	$166.7M	$38.4M
Assets, Current	$39.6M	$89.1M	$108.7M	$152.3M	$37.7M
Cash and Cash Equivalents, at Carrying Value	$36.1M	$59.4M	$72.6M	$74.9M	$37.1M
Accounts Receivable, after Allowance for Credit Loss, Current	—	—	$12.4K	$246.0K	$500.1K
Liabilities	$11.3M	$12.0M	$12.5M	$10.7M	$2.8M
Liabilities, Current	$7.5M	$7.8M	$8.1M	$5.6M	$2.3M
Accounts Payable, Current	$2.0M	$2.1M	$3.2M	$1.4M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$55.0M	-$49.0M	-$44.1M	-$30.9M	-$14.6M
Net Cash Provided by (Used in) Investing Activities	$26.4M	$7.3M	$41.8M	-$75.6M	-$53.4K
Net Cash Provided by (Used in) Financing Activities	$5.3M	$28.4M	$19.0K	$144.3M	$38.0M
Payments to Acquire Property, Plant, and Equipment	$84.9K	$342.7K	$742.5K	$60.8K	$53.4K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)